Peter S. Amenta, MD, PhD, dean of UMDNJ-Robert Wood Johnson Medical School, elected to 3-year term

Peter S. Amenta, MD, PhD, dean of UMDNJ-Robert Wood Johnson Medical School, has been elected to the Board of Trustees of the Joslin Diabetes Center for a three-year term. The center, affiliated with Harvard Medical School, is the world's largest diabetes clinic, diabetes research center and provider of diabetes education. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and to offering real hope and progress toward diabetes prevention and, ultimately, a cure.

“We are delighted to have Dr. Amenta on board, as we can learn from the advances he is directing in education, research, patient care, and community health,” says John L. Brooks III, president and chief executive officer of the Joslin Diabetes Center. “As we see healthcare and healthcare reform dramatically shaping the way Joslin will be delivering excellence in cost-effective diabetes care going forward, we are fortunate to learn and benefit from Dr. Amenta's leadership and innovative thinking.”

Dr. Amenta was named dean of Robert Wood Johnson Medical School in 2008, after serving as interim dean for more than two years. Dr. Amenta has been a member of the Robert Wood Johnson Medical School faculty since 1989 and was chair of the Department of Pathology and Laboratory Medicine from 1998-2008. For more than a decade, he served as residency program director and chief of the pathology service at Robert Wood Johnson University Hospital, where he also served as senior vice president of medical affairs and chief of staff from 2002-2006.  

Dr. Amenta received his Bachelor of Science degree from Trinity College in Hartford, Connecticut.  He completed his pathology residency at Hahnemann University in Philadelphia, PA, where he also received his medical degree and obtained a PhD in anatomy.  
“I am honored to work with the Board of Trustees and the leadership of the Joslin Diabetes Center,” says Dr. Amenta. “The Center’s dedication to helping improve the lives of individuals living with diabetes now and in the future through research, education and care is a model for others to emulate.”

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment